Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - 2008
Newron announces completion of patient enrollment in phase III clinical trial of safinamide in mid- to late-stage Parkinson’s Disease22/05/2008 | 
ENG
| 
GER
| |
Newron closes acquisition of Hunter-Fleming14/05/2008 |
ENG
|
GER
| |
Newron acquisition of Hunter-Fleming. Upfront payment agreed.29/04/2008 |
ENG
|
GER
| |
Newron shareholders’ meeting25/04/2008 |
ENG
|
GER
| |
NEWRON TO BE INCLUDED IN SWISS PERFORMANCE INDEX OF THE SWISS STOCK EXCHANGE (“SWX”) EFFECTIVE 6 MAY 200823/04/2008 |
ENG
|
GER
| |
Newron reports positive Phase II results for ralfinamide in peripheral neuropathic pain patients16/04/2008 |
ENG
|
GER
| |
Newron to present Phase II clinical data on ralfinamide in neuropathic pain at the AAN09/04/2008 |
ENG
|
GER
| |
NEWRON PHARMACEUTICALS REPORTS 2007 RESULTS27/03/2008 |
ENG
|
GER
| |
Data safety monitoring board recommends continuation of phase II study for HF0220 in patients with Alzheimer’s disease03/03/2008 |
ENG
|
GER
| |
Safinamide patent protection strengthened by EPO Intention-to-Grant-letter26/02/2008 |
ENG
|
GER
| |
Newron completes enrolment of clinical phase II study with ralfinamide in post-surgical (dental) pain19/02/2008 |
ENG
|
GER
| |
Newron acquires Hunter-Fleming Ltd11/02/2008 |
ENG
|
GER
| |
Dr. Hans-Joachim Lohrisch joins Newron’s Board of Directors14/01/2008 |
ENG
|
GER
|